TL;DR: On August 19, 2026, Moderna and Merck said their personalized mRNA therapy intismeran autogene plus Keytruda met its main goals in a 1,137-patient Phase 3 melanoma trial, delaying return and distant spread after surgery.

On August 19, 2026, Moderna and Merck announced positive topline results from the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda in completely resected high-risk melanoma, according to Personalized mRNA Cancer Therapy Reaches a Phase 3 Milestone in Melanoma. The randomized study enrolled 1,137 patients and met its primary endpoint of recurrence-free survival as well as a key secondary endpoint of distant metastasis-free survival at a prespecified interim analysis. The companies described the improvements over pembrolizumab alone as statistically significant and clinically meaningful. Moderna and Merck described INTerpath-001 as the first positive Phase 3 readout for an individualized neoantigen therapy and for an mRNA-based cancer therapy. The announcement does not include hazard ratios, event counts, survival curves, or subgroup results, and overall survival remains under follow-up. The study continues under protocol while fuller results are prepared for presentation at a medical meeting.

A first late-stage signal after a long history of misses

The August 28, 2026 Reuters report titled Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough framed the readout as the first success of a therapeutic cancer vaccine in late-stage testing after more than 100 years of failed attempts. That report described a trial of more than 1,000 patients with localized melanoma in which the vaccine kept tumors from coming back or spreading. Cancer experts cited in that reporting described the approach as the beginning of an era of custom-made vaccines that train the immune system to fight an individual patient's cancer. With full trial details pending, outside physicians have stressed that the public evidence remains limited to a company announcement. The available interim data showed the experimental vaccine, when combined with Merck's immunotherapy Keytruda, helped reduce the risk of melanoma recurrence and spread in patients whose tumors had been surgically removed, according to Moderna cancer vaccine shows promise in melanoma trial results from USA Today.

What INTerpath-001 tested

INTerpath-001 is identified as NCT05933577, a randomized, double-blind, placebo- and active-comparator-controlled Phase 3 trial, according to Intismeran Meets Phase 3 Endpoints in Resected Melanoma. It enrolled patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma who had not received prior systemic therapy. Participants were randomized 2:1 to intismeran plus Keytruda or to Keytruda alone. The trial design focuses on the adjuvant setting, meaning patients had already undergone complete surgical resection but remained at elevated risk of disease recurrence, according to Personalized mRNA Cancer Therapy Reaches a Phase 3 Milestone in Melanoma. Recurrence-free survival, the primary endpoint, was defined as time from randomization to local, locoregional, regional or distant recurrence, or death from any cause, as assessed by the investigator. Secondary endpoints include distant metastasis-free survival, overall survival, safety, tolerability and quality of life. Treatment was planned to continue for approximately one year, until recurrence or unacceptable toxicity, or for a maximum of approximately 56 weeks.

Dosing schedule used in the two groups

Patients assigned to the experimental group received intismeran at 1 mg every three weeks for up to nine doses, according to Landmark Phase III Win for Personalized mRNA Cancer Therapy. Pembrolizumab was administered at 400 mg every six weeks for up to nine cycles. The control group received pembrolizumab with placebo on the same pembrolizumab schedule. The combination period ran about a year and was capped near 56 weeks, according to Intismeran Meets Phase 3 Endpoints in Resected Melanoma. The primary endpoint counts any local, locoregional, regional or distant recurrence, or death from any cause. Distant metastasis-free survival, overall survival, safety, tolerability and quality of life are key secondary endpoints, and the companies said the study continues so those longer-term outcomes can mature. Safety in both arms matched what earlier studies of the combination had shown, with no new signals identified.

How each dose is built for one patient

Unlike a conventional vaccine produced as the same formulation for many people, intismeran autogene is designed individually based on the molecular characteristics of each patient's tumor, according to Personalized mRNA Cancer Therapy Reaches a Phase 3 Milestone in Melanoma. Scientists analyze a sample of the patient's tumor and use its unique genetic features to create an mRNA treatment designed to help the immune system recognize and attack that cancer, according to Personalised mRNA therapy reduces risk of melanoma returning in Phase 3 trial from UCLH. Tumor sequencing is used to identify patient-specific mutations, from which candidate neoantigens are selected. Intismeran consists of synthetic mRNA encoding up to 34 selected neoantigens, with the goal of generating or expanding T-cell responses against the patient's tumor. Once surgeons remove a tumor or cancerous lesion, the companies sequence it, looking for unique cancer mutations, and use those to create a customized product known as intismeran autogene, also called V940 and mRNA-4157. Combining this individualized approach with anti-PD-1 therapy may strengthen immune recognition while limiting tumor-mediated immune suppression.

U.K. role and hospital contribution

An international Phase 3 trial led in the U.K. by University College London Hospitals reported positive early results for the personalized mRNA treatment designed to stop high-risk melanoma returning after surgery, according to Personalised mRNA therapy reduces risk of melanoma returning in Phase 3 trial. The INTerpath-001 trial is testing intismeran autogene, also known as V940, in combination with pembrolizumab. UCLH coordinated the U.K. recruitment to the trial, and U.K. centres went on to recruit nearly 5% of all participants in the global Phase 3 trial. Cancer research at UCLH is supported in underlying infrastructure by the National Institute for Health and Care Research. Dr. Heather Shaw, UCLH consultant medical oncologist and U.K. coordinating investigator for INTerpath-001, said the result was an important moment for melanoma research. Full results, including the size of the benefit, will be presented at the European Society for Medical Oncology Congress in October, according to the UCLH report. Patients in the trial will continue to be followed, including to see whether the treatment helps people live longer.

What doctors leading the study said

Georgina Long, medical director of Melanoma Institute Australia and chair of melanoma medical oncology and translational research at the University of Sydney, led the trial and supplied a clinical characterization of the result, according to Intismeran Meets Phase 3 Endpoints in Resected Melanoma. She said the findings represented a landmark moment for adjuvant melanoma treatment involving a treatment designed around the unique mutational fingerprint of a patient's own tumor with pembrolizumab. Dean Y. Li, president of Merck Research Laboratories, said the partners will present INTerpath-001 at an international medical meeting and share the findings with regulatory authorities. Dr. Heather Shaw said every patient's treatment is individually designed to help the immune system recognize its own cancer. Shaw also said researchers do not yet know the size of the benefit and need to see full results before understanding how the treatment might fit into clinical practice. The UCLH account said the companies reported no new safety concerns.

Why melanoma was the first test case

Melanoma is the most serious form of skin cancer and the fifth most common cancer in the U.K., with around 19,400 new cases diagnosed each year, according to Personalised mRNA therapy reduces risk of melanoma returning in Phase 3 trial. Surgery can cure many melanomas, but in people with higher-risk disease there remains a risk that cancer will return. Treatments such as pembrolizumab are already given after surgery to reduce that risk. INTerpath-001 is investigating whether adding a treatment designed specifically for each patient's tumor can reduce that risk further. Daina Graybosch of Leerink Partners called melanoma uniquely suited to a vaccine, according to Intismeran Meets Phase 3 Endpoints in Resected Melanoma. The report also noted that per-patient manufacturing costs for a therapy of this kind are likely higher than for a standard biologic drug. It cautioned that assuming success in other tumor types may be a flawed assumption. The personalized therapy remains investigational until detailed efficacy, overall survival, presentation and regulatory review are complete.

Earlier Phase 2b results that set expectations

Earlier evidence came from the randomized Phase 2b KEYNOTE-942 study of 157 patients, whose five-year follow-up was presented at the 2026 American Society of Clinical Oncology annual meeting, according to Personalized mRNA Cancer Therapy Reaches a Phase 3 Milestone in Melanoma. At five years, intismeran plus pembrolizumab was associated with a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death compared with pembrolizumab alone. The detailed figures were hazard ratio 0.51 with 95% confidence interval 0.294 to 0.887 for recurrence or death, and hazard ratio 0.411 with 95% confidence interval 0.200 to 0.843 for distant metastasis or death, according to Intismeran Meets Phase 3 Endpoints in Resected Melanoma. Overall survival data remained immature, with only a limited number of deaths observed. Moderna management has treated a 20% reduction in the risk of recurrence or death as the program's clinical benchmark, according to analyst notes summarized in that report. Cory Kasimov of Evercore ISI wrote that a 35% to 40% reduction would read as clearly differentiated.

What remains undisclosed

As of the initial August 19 announcement, Moderna and Merck had not publicly disclosed key numerical Phase 3 results such as hazard ratios, confidence intervals, event numbers, Kaplan-Meier curves, or detailed subgroup analyses, according to Personalized mRNA Cancer Therapy Reaches a Phase 3 Milestone in Melanoma. Numerical efficacy estimates, confidence intervals, follow-up duration and detailed subgroup findings were also listed as undisclosed in Landmark Phase III Win for Personalized mRNA Cancer Therapy. The announcement was described as a topline interim result, not a regulatory decision, and no application had been filed, according to Intismeran Meets Phase 3 Endpoints in Resected Melanoma. The companies have indicated that complete data will be presented at an upcoming international medical meeting, with UCLH specifying the European Society for Medical Oncology Congress in October. For that reason, the magnitude of the Phase 3 benefit cannot yet be independently assessed from publicly available information. Detailed results will be needed to determine not only statistical significance but clinical relevance and which patients benefit most.

Market reaction on the announcement day

Moderna's share price rose more than 170% on August 19, adding close to $45 billion in market value in a single session and pulling Merck and BioNTech up by double digits, for roughly $92 billion in combined gains, according to BioPharma Dive reporting summarized in Intismeran Meets Phase 3 Endpoints in Resected Melanoma. Myles Minter of William Blair upgraded Moderna and modeled $5.4 billion in peak annual melanoma sales for the company under its 50-50 revenue split with Merck. Cory Kasimov of Evercore ISI wrote that the new valuation already reflected substantially more conviction than the data disclosed thus far. The market discussion treated the Phase 2b five-year figures as the bar for interpreting an undisclosed Phase 3 effect size. No hazard ratios, event counts or survival curves accompanied the August 19 announcement. The full dataset remains held for presentation, leaving valuation models dependent on a press release and on data seen by people the rest of the field had not seen.

What comes next for review and access

Merck and Moderna said INTerpath-001 will continue to assess overall survival and other secondary outcomes, according to Landmark Phase III Win for Personalized mRNA Cancer Therapy. The sponsors announced that the study met its main goal, with patients receiving the personalized treatment alongside pembrolizumab going significantly longer without melanoma returning than those receiving pembrolizumab alone, according to Personalised mRNA therapy reduces risk of melanoma returning in Phase 3 trial. The combination also significantly delayed cancer spreading to other parts of the body. The companies said no new safety concerns were identified. The next important question is no longer simply whether the approach can reach late-stage development, but how substantial the benefit is, which patients are most likely to benefit, and whether the strategy can be extended to other cancers, according to Personalized mRNA Cancer Therapy Reaches a Phase 3 Milestone in Melanoma. The INTerpath-001 announcement does not yet establish that individualized mRNA therapy improves overall survival, nor does success in melanoma guarantee similar outcomes elsewhere.

Sources referenced